Over the past decade, adeno-associated virus (AAV) vectors have received increasing attention in basic, preclinical, and clinical research, and AAV vectors are now one of the most promising vector systems for gene therapy applications. This is partly because AAV is not associated with any known human disease, AAV vectors can produce long-term transgene expression at least in non-dividing cells (even in the absence of genomic integration), and AAV exhibits relatively low immunogenicity.
The AAV 4.6 kb single-stranded DNA genome contains two viral genes: rep and cap. These genes can be removed and replaced with a cassette that expresses a therapeutic transgene, along with the necessary rep and cap genes. The cap gene encodes three proteins, VP1, VP2, and VP3, of which 60 VP monomers make up the complete icosahedral AAV capsid, with a VP1:VP2:VP3 ratio of 1:1:10. The VP1 and VP2 proteins each contain the complete VP3 amino acid sequence, which constitutes the structure of the capsid. Unique regions of VP1 and VP2 perform additional functions, such as endosomal escape. VP3 contains nine flexible loops called hypervariable regions (HVRs) that account for the majority of sequence and structural variation among AAV serotypes, which are organized into larger groups called clades based on shared sequences. These variations confer unique properties to these serotypes, such as receptor binding, tissue tropism, and antigenicity.
Voltage-dependent anion channel 2 (VDAC2) is a mitochondrial outer membrane porin known to play an important role in apoptosis and calcium signaling. To elucidate the role of VDAC2 in calcium homeostasis, researchers generated a ventricular myocyte-specific developmental deletion of Vdac2 in mice. These results show that the loss of VDAC2 in the myocardium leads to a severe impairment of excitation-contraction coupling by altering intracellular and mitochondrial calcium signaling. Researchers also observed adverse cardiac remodeling that progressed to severe cardiomyopathy and death. Reintroduction of VDAC2 in 6-week-old knockout mice partially rescued the cardiomyopathy phenotype. In a mouse model of pressure overload-induced heart failure, activation of VDAC2 by efsevin increased cardiac contractility. Together, these results suggest that VDAC2 plays a critical role in cardiac function by affecting cellular calcium signaling.
Here, researchers evaluated the cardiac ventricular myocyte-specific reintroduction of VDAC2 in KO and WT mice using western blotting and qRT-PCR (Figure 1a, b). Serial echocardiography was performed in these mice until 10 weeks after injection (16-week-old mice) to obtain comparable results. Compared with KO mice injected with the control AAV9-αMHC-GFP vector, KO mice injected with the AAV9-αMHC-VDAC2-GFP vector showed relative improvement in EF, FS, and LV volume, and a decrease in LV diameter, and improved cardiac structure and function were observed (Figure 1c-g). Complete restoration of the phenotype was not observed, however, reintroduction of VDAC2 contributed to improved cardiac function.
Figure 1. Partial rescue of HF phenotype upon VDAC2 reintroduction. (Shankar T S, et al., 2021)
Customer Reviews
Reproducible Results
Across multiple experiments, we observed reproducible results with high GFP expression levels in cardiac cells. This consistency makes it an invaluable tool for any cardiac research project focused on gene expression analysis.
Write a Review